Professor Harvey Lodish, Professor Dario Campana and Professor Antonio Bertoletti have all been scientific founders of biotech companies (Rubius Therapeutics, Unum, MediSix, LionTCR, etc.) in both the U.S. and Singapore.
Prof. Harvey Lodish, is a Founding Member of The Whitehead Institute as well as the Founder & Scientific Advisory board member of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals, Allozyne, Rubius Therapeutics and several other biotech companies.
Prof. Dario Campana serves as the Scientific Founder of Unum Therapeutics, Inc. and has been its Chairman of Advisory Board since February 2, 2016. In addition, he is also a Founder at Medisix Therapeutics Pte Ltd. as well as Scientific Advisor at Lion TCR and was a Member of Medical Advisory Board at Cellectis S.A. He is considered a pioneer in the field of cancer cell therapies and has dedicated his career to translational oncology research. Unum Therapeutics also recently went public earlier this year.
Prof. Antonio Bertoletti is the current Vice-President of the Singapore Society of Immunology and the research in his laboratories (Duke-NUS Emerging Viral Diseases Program and SICS- A-STAR) focusing on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and Hepatocellularcarcinoma and on the characterization of human intrasinusoidal hepatic immune system. With his expertise, Dr. Bertoletti is also the Scientific Founder of Lion TCR.
In light of the insights to be gained from all their work and experiences, we hope that you will join us for this upcoming event on the 22nd January, 2019. See you there!